Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: A randomised clinical trial

Marco Gambacciani, Patrizia Monteleone, Cristiana Vitale, Antonello Silvestri, Massimo Fini, Andrea R. Genazzani, Giuseppe M C Rosano

Research output: Contribution to journalArticle

Abstract

Objectives: The purpose of this study was to evaluate endothelium-dependent flow-mediated dilation (FMD) in the brachial artery and the plasma levels of endothelin-1 in postmenopausal women at risk for coronary artery disease before and after treatment with both estradiol and estradiol plus dydrogesterone. Methods: Sixteen postmenopausal women (PMW) (mean age 58±9 years) with more than two risk factors for coronary artery disease, were randomized to receive either oral estradiol (2 mg) for 28 days or oral estradiol (2 mg) for 14 days and oral estradiol (2 mg) and dydrogesterone (10 mg) for 14 days, in a double-blind, placebo-controlled, single cross-over study. Patients were crossed-over the complementary treatment 7 days after completing the first treatment. The study of forearm blood flow and the measurement of plasma endothelin-1 levels was carried out before and after each treatment. Results: Estradiol significantly increased FMD as compared to baseline; the addition of dydrogesterone did not affect the effect of estradiol on FMD. Similarly reactive hyperemic flow increased after estradiol alone or in association with dydrogesterone compared to baseline. Plasma levels of endothelin-1 were significantly reduced by estradiol both when administered alone or in association with dydrogesterone. Conclusions: Hormone replacement therapy with estradiol and dydrogesterone improves endothelial function and reduces plasma levels of endothelin-1 in PMW at risk for coronary artery disease.

Original languageEnglish
Pages (from-to)117-123
Number of pages7
JournalMaturitas
Volume43
Issue number2
DOIs
Publication statusPublished - Oct 25 2002

Fingerprint

Dydrogesterone
Vasodilation
Endothelium
Estradiol
Randomized Controlled Trials
Endothelin-1
Plasmas
Coronary Artery Disease
Dilatation
Brachial Artery
Hormone Replacement Therapy
Therapeutics
Forearm
Cross-Over Studies

Keywords

  • Coronary artery disease
  • Dydrogesterone
  • Hormone replacement therapy

ASJC Scopus subject areas

  • Ageing
  • Obstetrics and Gynaecology

Cite this

Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women : A randomised clinical trial. / Gambacciani, Marco; Monteleone, Patrizia; Vitale, Cristiana; Silvestri, Antonello; Fini, Massimo; Genazzani, Andrea R.; Rosano, Giuseppe M C.

In: Maturitas, Vol. 43, No. 2, 25.10.2002, p. 117-123.

Research output: Contribution to journalArticle

@article{965b36d3bdc74a80be9cb542f6f3fd16,
title = "Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: A randomised clinical trial",
abstract = "Objectives: The purpose of this study was to evaluate endothelium-dependent flow-mediated dilation (FMD) in the brachial artery and the plasma levels of endothelin-1 in postmenopausal women at risk for coronary artery disease before and after treatment with both estradiol and estradiol plus dydrogesterone. Methods: Sixteen postmenopausal women (PMW) (mean age 58±9 years) with more than two risk factors for coronary artery disease, were randomized to receive either oral estradiol (2 mg) for 28 days or oral estradiol (2 mg) for 14 days and oral estradiol (2 mg) and dydrogesterone (10 mg) for 14 days, in a double-blind, placebo-controlled, single cross-over study. Patients were crossed-over the complementary treatment 7 days after completing the first treatment. The study of forearm blood flow and the measurement of plasma endothelin-1 levels was carried out before and after each treatment. Results: Estradiol significantly increased FMD as compared to baseline; the addition of dydrogesterone did not affect the effect of estradiol on FMD. Similarly reactive hyperemic flow increased after estradiol alone or in association with dydrogesterone compared to baseline. Plasma levels of endothelin-1 were significantly reduced by estradiol both when administered alone or in association with dydrogesterone. Conclusions: Hormone replacement therapy with estradiol and dydrogesterone improves endothelial function and reduces plasma levels of endothelin-1 in PMW at risk for coronary artery disease.",
keywords = "Coronary artery disease, Dydrogesterone, Hormone replacement therapy",
author = "Marco Gambacciani and Patrizia Monteleone and Cristiana Vitale and Antonello Silvestri and Massimo Fini and Genazzani, {Andrea R.} and Rosano, {Giuseppe M C}",
year = "2002",
month = "10",
day = "25",
doi = "10.1016/S0378-5122(02)00184-6",
language = "English",
volume = "43",
pages = "117--123",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women

T2 - A randomised clinical trial

AU - Gambacciani, Marco

AU - Monteleone, Patrizia

AU - Vitale, Cristiana

AU - Silvestri, Antonello

AU - Fini, Massimo

AU - Genazzani, Andrea R.

AU - Rosano, Giuseppe M C

PY - 2002/10/25

Y1 - 2002/10/25

N2 - Objectives: The purpose of this study was to evaluate endothelium-dependent flow-mediated dilation (FMD) in the brachial artery and the plasma levels of endothelin-1 in postmenopausal women at risk for coronary artery disease before and after treatment with both estradiol and estradiol plus dydrogesterone. Methods: Sixteen postmenopausal women (PMW) (mean age 58±9 years) with more than two risk factors for coronary artery disease, were randomized to receive either oral estradiol (2 mg) for 28 days or oral estradiol (2 mg) for 14 days and oral estradiol (2 mg) and dydrogesterone (10 mg) for 14 days, in a double-blind, placebo-controlled, single cross-over study. Patients were crossed-over the complementary treatment 7 days after completing the first treatment. The study of forearm blood flow and the measurement of plasma endothelin-1 levels was carried out before and after each treatment. Results: Estradiol significantly increased FMD as compared to baseline; the addition of dydrogesterone did not affect the effect of estradiol on FMD. Similarly reactive hyperemic flow increased after estradiol alone or in association with dydrogesterone compared to baseline. Plasma levels of endothelin-1 were significantly reduced by estradiol both when administered alone or in association with dydrogesterone. Conclusions: Hormone replacement therapy with estradiol and dydrogesterone improves endothelial function and reduces plasma levels of endothelin-1 in PMW at risk for coronary artery disease.

AB - Objectives: The purpose of this study was to evaluate endothelium-dependent flow-mediated dilation (FMD) in the brachial artery and the plasma levels of endothelin-1 in postmenopausal women at risk for coronary artery disease before and after treatment with both estradiol and estradiol plus dydrogesterone. Methods: Sixteen postmenopausal women (PMW) (mean age 58±9 years) with more than two risk factors for coronary artery disease, were randomized to receive either oral estradiol (2 mg) for 28 days or oral estradiol (2 mg) for 14 days and oral estradiol (2 mg) and dydrogesterone (10 mg) for 14 days, in a double-blind, placebo-controlled, single cross-over study. Patients were crossed-over the complementary treatment 7 days after completing the first treatment. The study of forearm blood flow and the measurement of plasma endothelin-1 levels was carried out before and after each treatment. Results: Estradiol significantly increased FMD as compared to baseline; the addition of dydrogesterone did not affect the effect of estradiol on FMD. Similarly reactive hyperemic flow increased after estradiol alone or in association with dydrogesterone compared to baseline. Plasma levels of endothelin-1 were significantly reduced by estradiol both when administered alone or in association with dydrogesterone. Conclusions: Hormone replacement therapy with estradiol and dydrogesterone improves endothelial function and reduces plasma levels of endothelin-1 in PMW at risk for coronary artery disease.

KW - Coronary artery disease

KW - Dydrogesterone

KW - Hormone replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=0037174973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037174973&partnerID=8YFLogxK

U2 - 10.1016/S0378-5122(02)00184-6

DO - 10.1016/S0378-5122(02)00184-6

M3 - Article

C2 - 12385860

AN - SCOPUS:0037174973

VL - 43

SP - 117

EP - 123

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - 2

ER -